APA 6th Edition KEHLER, T. i ČABRIJAN, L. (2015). ŠTO TREBA ZNATI O PSORIJATIČNOM ARTRITISU?. Acta medica Croatica, 69 (2), 111-115. Preuzeto s https://hrcak.srce.hr/147983
MLA 8th Edition KEHLER, TATJANA i LEO ČABRIJAN. "ŠTO TREBA ZNATI O PSORIJATIČNOM ARTRITISU?." Acta medica Croatica, vol. 69, br. 2, 2015, str. 111-115. https://hrcak.srce.hr/147983. Citirano 02.03.2021.
Chicago 17th Edition KEHLER, TATJANA i LEO ČABRIJAN. "ŠTO TREBA ZNATI O PSORIJATIČNOM ARTRITISU?." Acta medica Croatica 69, br. 2 (2015): 111-115. https://hrcak.srce.hr/147983
Harvard KEHLER, T., i ČABRIJAN, L. (2015). 'ŠTO TREBA ZNATI O PSORIJATIČNOM ARTRITISU?', Acta medica Croatica, 69(2), str. 111-115. Preuzeto s: https://hrcak.srce.hr/147983 (Datum pristupa: 02.03.2021.)
Vancouver KEHLER T, ČABRIJAN L. ŠTO TREBA ZNATI O PSORIJATIČNOM ARTRITISU?. Acta medica Croatica [Internet]. 2015 [pristupljeno 02.03.2021.];69(2):111-115. Dostupno na: https://hrcak.srce.hr/147983
IEEE T. KEHLER i L. ČABRIJAN, "ŠTO TREBA ZNATI O PSORIJATIČNOM ARTRITISU?", Acta medica Croatica, vol.69, br. 2, str. 111-115, 2015. [Online]. Dostupno na: https://hrcak.srce.hr/147983. [Citirano: 02.03.2021.]
Sažetak Psoriatic arthritis (PsA) is chronic inlammatory arthropathy of peripheral joints and axial sceleton, occurring in 7% to 42% of patients with psoriasis. Arthritis might precede skin psoriatic lesion lesion in 13% to 17% cases. Patients present with pain and stiffness of the affected joins. A genetic factors play an important role (B27 has been associated with axial form, and DR4 with peripheral polyarticular form of PsA). Enthesopathy is a hallmark feature of PsA. It is an inlammation at the sites where tendons and ligaments attach to the bone. Extra-articular manifestations of disease are conjuctivitis and uveitis (occur in up to 1/3 of patients with PsA), heart disorder (aortic insuficiency), gut inlammation, urogenital inlammation.Treatment of PsA includes therapies for boths the skin and the joint disease. The treatment for the joint disease includes using NSAR (nonsteroidal anti-inlammatory drugs), DMARDs (Disease-Modifying Antirheumatic Drugs) such as methotrexat (MTX), lelunomid, sulfasalasin and biological agents. Second-line therapy are: systemic glucocorticoids, retinoic acid derivatives/etretinate, photochemoterapy with MTX, physical therapy as an adjunct to drug therapy, and reconstructive surgery. The most important is that rheumatologist and dermatologist need to have some approach in management of PsA for optimal results.